Trial Profile

A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navicixizumab (Primary)
Indications Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors OncoMed Pharmaceuticals

Most Recent Events

27 May 2021 According to an OncoMed Pharmaceuticals media release, this study has conducted in partnership with OncXerna Therapeutics.
13 Jan 2020 Results presented in a Mereo BioPharma media release.
07 Oct 2019 Results published in the Mereo BioPharma Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com